Abstract

Antineoplasic-induced nausea and vomiting (AINV) are adverse events with negatively impact on the quality of life of cancer patients and may contribute to non- adherence to treatment. The present investigation is a study of availability analyses that offers the opportunity to know the profile of medicines available for use in a health system and aims to analyze the supply of antiemetics for AINV registered in Brazilian Health Regulatory Agency (Anvisa). The drugs available for use in clinical practice included in group A04A - Antiemetics and Antinauseants of the ATC classification were identified on the site WHO Collaborating Center for Drug Statistics Methodology and was searched in the electronic base “Consultation of Regularized Products - Drugs” from ANVISA the drugs of the group A04A registered, their pharmaceutical forms and the availability of Generic. Bibliographic research was conducted to identify clinical guidelines for the treatment of AINV and the recommended drugs. Abroad, four scientific societies of oncology (ASCO, MASC / ESMO, NCCN and SEOM) provide clinical guidelines. In Brazil, drugs from all major classes are registered for the treatment of AINV. Thus, although the guideline publication elaborated by Brazilian scientific societies has not been identified, there are resources compatible with the recommendations of the international guidelines for adequate approach to the AINV. Oncology services should select antiemetics based on international guidelines, taking into account cost to the health system, effectiveness and safety.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call